Rohini Chitra

1.1k total citations
17 papers, 929 citations indexed

About

Rohini Chitra is a scholar working on Surgery, Pharmacology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Rohini Chitra has authored 17 papers receiving a total of 929 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Surgery, 4 papers in Pharmacology and 4 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Rohini Chitra's work include Lipoproteins and Cardiovascular Health (8 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (4 papers) and Pharmaceutical Economics and Policy (4 papers). Rohini Chitra is often cited by papers focused on Lipoproteins and Cardiovascular Health (8 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (4 papers) and Pharmaceutical Economics and Policy (4 papers). Rohini Chitra collaborates with scholars based in United States, Canada and India. Rohini Chitra's co-authors include Evan A. Stein, Howard G. Hutchinson, Richard Entsuah, Michael H. Davidson, Steven G. Simonson, Antonio M. Gotto, Christie M. Ballantyne, Ali Raza, Dennis W. Schneck and Patrick Ma and has published in prestigious journals such as The American Journal of Cardiology, American Heart Journal and Headache The Journal of Head and Face Pain.

In The Last Decade

Rohini Chitra

16 papers receiving 878 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rohini Chitra United States 11 654 314 262 177 103 17 929
U. Jeppesen Denmark 8 171 0.3× 29 0.1× 66 0.3× 49 0.3× 204 2.0× 10 824
Charlie Cao United States 13 275 0.4× 17 0.1× 489 1.9× 26 0.1× 75 0.7× 25 1.4k
Bret J. Musser United States 14 257 0.4× 55 0.2× 689 2.6× 12 0.1× 271 2.6× 24 1.3k
Jun Cheng China 16 108 0.2× 40 0.1× 94 0.4× 62 0.4× 33 0.3× 36 855
Philippe Sellier France 16 257 0.4× 110 0.4× 98 0.4× 26 0.1× 38 0.4× 56 982
Jean Ducobu Belgium 16 138 0.2× 41 0.1× 157 0.6× 28 0.2× 49 0.5× 68 690
Krassimir Kalinov Bulgaria 18 253 0.4× 11 0.0× 435 1.7× 51 0.3× 21 0.2× 51 837
Yaoyao Bian China 20 173 0.3× 15 0.0× 80 0.3× 74 0.4× 224 2.2× 57 1.1k
G R Venning United Kingdom 10 97 0.1× 59 0.2× 13 0.0× 41 0.2× 106 1.0× 20 719
Gianandrea Bertone Italy 8 114 0.2× 18 0.1× 400 1.5× 37 0.2× 105 1.0× 14 648

Countries citing papers authored by Rohini Chitra

Since Specialization
Citations

This map shows the geographic impact of Rohini Chitra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rohini Chitra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rohini Chitra more than expected).

Fields of papers citing papers by Rohini Chitra

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rohini Chitra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rohini Chitra. The network helps show where Rohini Chitra may publish in the future.

Co-authorship network of co-authors of Rohini Chitra

This figure shows the co-authorship network connecting the top 25 collaborators of Rohini Chitra. A scholar is included among the top collaborators of Rohini Chitra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rohini Chitra. Rohini Chitra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
3.
Hellriegel, Edward T., Ernesto Aycardi, Marcelo E. Bigal, et al.. (2016). A Phase I, Open‐Label, Single‐Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients. Headache The Journal of Head and Face Pain. 56(8). 1300–1309. 5 indexed citations
4.
Chitra, Rohini. (2014). EFFECT OF LUMBAR STABILIZATION EXERCISE AND LUMBAR EXTENSION EXERCISE IN THE TREATMENT OF CHRONIC LOW BACK PAIN. European Scientific Journal ESJ. 10(21). 4 indexed citations
5.
Chitra, Rohini, et al.. (2011). A systems biological study on the comorbidity of autism spectrum disorders and bipolar disorder. Bioinformation. 7(3). 102–106. 10 indexed citations
6.
Kallend, David, Ole Færgeman, & Rohini Chitra. (2005). W16-P-041 Comparison of the efficacy of rosuvastatin versus other statins in achieving 2003 European LDL-C goals. Atherosclerosis Supplements. 6(1). 110–111. 1 indexed citations
7.
Hunninghake, Donald B., Evan A. Stein, Harold Bays, et al.. (2004). Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia. Coronary Artery Disease. 15(2). 115–123. 61 indexed citations
8.
Ballantyne, Christie M., Elinor Miller, & Rohini Chitra. (2004). Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: A randomized, open-label, multicenter trial. Clinical Therapeutics. 26(11). 1855–1864. 24 indexed citations
9.
Blasetto, James W., Evan A. Stein, W. Virgil Brown, Rohini Chitra, & Ali Raza. (2003). Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. The American Journal of Cardiology. 91(5). 3–10. 125 indexed citations
10.
Schneck, Dennis W., Robert H. Knopp, Christie M. Ballantyne, et al.. (2003). Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. The American Journal of Cardiology. 91(1). 33–41. 123 indexed citations
11.
Capuzzi, David M., John Morgan, Robert Weiss, et al.. (2003). Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. The American Journal of Cardiology. 91(11). 1304–1310. 60 indexed citations
12.
Brown, W. Virgil, Harold Bays, David Hassman, et al.. (2002). Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial. American Heart Journal. 144(6). 1036–1043. 136 indexed citations
13.
Davidson, Michael H., Patrick Ma, Evan A. Stein, et al.. (2002). Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. The American Journal of Cardiology. 89(3). 268–275. 205 indexed citations
14.
Gallagher, R. Michael, George W. Dennish, Egilius L.H. Spierings, & Rohini Chitra. (2000). A Comparative Trial of Zolmitriptan and Sumatriptan for the Acute Oral Treatment of Migraine. Headache The Journal of Head and Face Pain. 40(2). 119–128. 55 indexed citations
15.
Rudolph, Richard L., Richard Entsuah, & Rohini Chitra. (1998). A Meta-Analysis of the Effects of Venlafaxine on Anxiety Associated With Depression. Journal of Clinical Psychopharmacology. 18(2). 136–144. 63 indexed citations
16.
Entsuah, Richard & Rohini Chitra. (1997). A benefit-risk analysis of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression.. PubMed. 33(4). 671–6. 29 indexed citations
17.
Entsuah, A.R., Richard L. Rudolph, & Rohini Chitra. (1995). Effectiveness of venlafaxine treatment in a broad spectrum of depressed patients: a meta-analysis.. PubMed. 31(4). 759–66. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by U. Jeppesen Breakdown of academic impact, for papers by Charlie Cao Breakdown of academic impact, for papers by Bret J. Musser Breakdown of academic impact, for papers by Jun Cheng Breakdown of academic impact, for papers by Philippe Sellier Breakdown of academic impact, for papers by Jean Ducobu Breakdown of academic impact, for papers by Krassimir Kalinov Breakdown of academic impact, for papers by Yaoyao Bian Breakdown of academic impact, for papers by G R Venning Breakdown of academic impact, for papers by Gianandrea Bertone
Rankless by CCL
2026